Prosecution Insights
Last updated: April 19, 2026

Examiner: NGUYEN, NAM P

Tech Center 1600 • Art Units: 1641 1677 1678

This examiner grants 55% of resolved cases

Performance Statistics

54.8%
Allow Rate
-5.2% vs TC avg
374
Total Applications
+46.0%
Interview Lift
1405
Avg Prosecution Days
Based on 325 resolved cases, 2023–2026

Rejection Statute Breakdown

4.5%
§101 Eligibility
16.1%
§102 Novelty
36.1%
§103 Obviousness
23.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18669218 SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRY Final Rejection Genentech, Inc.
18412316 USE OF DIVALENT METALS FOR ENHANCEMENT OF FLUORESCENT SIGNALS Non-Final OA SONY GROUP CORPORATION
17204253 NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN Non-Final OA Regeneron Pharmaceuticals, Inc.
17625351 LIGANDS FOR CAPTURING MICROVESICLES AND USES THEREOF Non-Final OA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
18480489 TEMPORAL TRAUMATIC BRAIN INJURY BIOMARKERS AND METHODS OF USE THEREOF Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
16523871 POLYMERIC TANDEM DYES HAVING PENDANT NARROW EMISSION ACCEPTOR Non-Final OA Becton, Dickinson and Company
18299833 POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT Non-Final OA SYSMEX CORPORATION
16971431 FC-BINDING PROTEIN HAVING IMPROVED ACID STABILITY, PRODUCTION METHOD FOR SAID PROTEIN, AND ANTIBODY-ADSORBING AGENT USING SAID PROTEIN Non-Final OA TOSOH CORPORATION
18349867 PEGBOARD PROTEIN PURIFICATION PLATE FOR HIGH THROUGHPUT PROTEIN CHARACTERIZATION Non-Final OA Alliance for Sustainable Energy, LLC
17265756 COMPOSITIONS AND METHODS FOR DETECTION AND IMAGING OF AMYLOID FIBRILS, AMYLOID PLAQUES, RNA, AND NUCLEOLI Non-Final OA The University of Hong Kong
17594470 METHODS FOR DETECTING ABERRANT RESULTS CAUSED BY INCOMPLETE DELIVERY OF A POLYHAPTEN REAGENT IN IMMUNOASSAYS Non-Final OA Siemens Healthcare Diagnostics Inc.
16442091 METHODS AND SYSTEMS FOR QUANTITATIVE IMMUNOHISTOCHEMISTRY Final Rejection Ventana Medical Systems, Inc.
18796204 METHODS OF PROCESSING A BIOFLUID SAMPLE Final Rejection PrognomiQ, Inc.
17838568 PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT Non-Final OA Roche Diagnostics Operations, Inc.
15892829 ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS Final Rejection Roche Diagnostics Operations, Inc.
18266665 METHOD FOR MEASURING RELATIVE fu RATIO BY DYNAMIC ANALYSIS Non-Final OA Chugai Seiyaku Kabushiki Kaisha
18380388 COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE Non-Final OA Pierce Biotechnology, Inc.
18221195 BIOCATALYTICAL COMPOSITION Non-Final OA Inofea GmbH
18271660 MARKER FOR ASSISTING IN DIAGNOSIS OF NEPHROTIC SYNDROME AND USE THEREOF Non-Final OA NIIGATA UNIVERSITY
17835026 Compositions and Methods to Expedite Antibody-Based Exchange Imaging Non-Final OA Ultivue, Inc.
18132746 COMPOSITIONS AND METHODS FOR THE DETECTION AND MOLECULAR PROFILING OF MEMBRANE BOUND VESICLES WITH NANOPARTICLES Non-Final OA The University of Memphis Research Foundation
18000355 NOVEL DIAGNOSTIC MARKER FOR PROSTATE CANCER Non-Final OA URTESTE S.A.
17817684 ADDITIVE, SURFACE TREATMENT AGENT, SURFACE-MODIFIED LATEX PARTICLES, METHOD FOR PRODUCING SURFACE-MODIFIED LATEX PARTICLES, REAGENT FOR LATEX AGGLUTINATION REACTION, KIT, AND METHOD FOR DETECTING TARGET SUBSTANCE Non-Final OA JSR LIFE SCIENCES CORPORATION
17740094 Tagged Compounds for Detection and Assay of Small Molecules Final Rejection AVETA LIFE, INC.
17687971 ANTI-CD40 ANTIBODIES AND USES THEREOF Non-Final OA BAYLOR RESEARCH INSTITUTE
17197828 AFFINITY SUPPORT AND METHOD FOR TRAPPING SUBSTANCE USING THE SAME Non-Final OA Biomolecular Holdings LLC
17142950 MAGNETO-PLASMONIC NANOMATERIALS AND METHODS OF USE Final Rejection Sogang University
15981767 METHODS FOR EXTRACTING AND MEASURING CONCENTRATIONS OF BIOMOLECULES IN COMPLEX MATRICES WITHOUT THE NEED FOR IMMUNOCAPTURE Final Rejection C2N DIAGNOSTICS LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month